

# HERPES SIMPLEX 2 VIRCLIA® IgM MONOTEST

For *in vitro* diagnostic use

**VCM041:** Indirect chemiluminescent immunoassay (CLIA) to test IgM antibodies against herpes simplex type 2 in human serum/plasma. 24 tests.

## INTRODUCTION:

Human infections with herpes simplex virus (HSV) are ubiquitous throughout the world. Primary infection is subclinical in a majority of cases. The most frequent manifestation of primary HSV-1 is pharyngitis and gingivostomatitis but other typical manifestations are conjunctivitis, keratitis, vesicular eruptions of skin, and encephalitis. HSV-2 is the most frequent agent of genital ulcers in the Western world and it can produce aseptic meningitis and neonatal herpes infection. The most used serological methods are complement fixation reaction, neutralization and enzyme-linked immunosorbent assay (ELISA). The immune response is stronger in the primary infection than during relapses. The two HSV types share many common epitopes that give rise to strongly cross-reacting antigens; therefore, it is difficult to achieve the serological differentiation between both types by using crude extracts. Yet, the use of purified viral proteins has led to the development of type-specific assays. The present kit uses purified gG-2 protein from herpes simplex type 2, allowing its specific diagnosis.

Detection methods based on chemiluminescence have received much attention due to their low background, linearity and wide dynamic range. When coupled to enzyme immunoassays, the signal amplification effect provided by the enzyme enables the design of CLIA (ChemiLuminescent ImmunoAssay) tests with shorter incubation times while keeping or improving their sensitivity.


## PRINCIPLE OF THE TEST:

The CLIA method is based upon the reaction of antibodies in the sample tested with the antigen adsorbed on the polystyrene surface. Unbound immunoglobulins are washed off. An enzyme-labelled anti-human globulin binds the antigen-antibody complex in a second step. After a new washing step, bound conjugate is developed with the aid of a chemiluminescent substrate solution that will generate a glow-type luminescence that can be read with a luminometer.

## KIT FEATURES:

All reagents supplied are ready to use.  
Serum dilution solution and conjugate are coloured to help in the performance of the technique.  
Sample predilution is not necessary.  
Reagents required for the run of the test are included in the monodose presentation.

## KIT CONTENTS:

 VIRCLIA® HERPES SIMPLEX 2 IgM MONODOSE: 24 monodoses consisting of 3 reaction wells and 5 reagent wells with the following composition:

Wells A, B, C: reaction wells; wells coated with purified inactivated virions of herpes simplex (HSV) type 2, strain MS.

Well D: Conjugate: orange; containing anti-human IgM peroxidase conjugate dilution and Neolone and Bronidox as preservatives.

Well E: Serum dilution solution: blue; phosphate buffer containing protein stabilizers, anti-human IgG and Neolone and Bronidox as preservatives.

Well F: Calibrator: clear; positive serum dilution containing Neolone and Bronidox as preservative.

Well G: Substrate component B: clear; containing peroxide.

Well H: Substrate component A: clear; containing luminol.

**Store at 2-8°C and check expiration date.**

## Materials required but not supplied:

- VIRCLIA® AUXILIARY REAGENTS (REF:VCMAR)
- Precision micropipettes 5 and 100 µl.
- Eight channel micropipette 100 µl.
- Adapted microplate washer.
- Thermostated incubator/water bath.
- Microplate luminometer.
- Alternatively, a CLIA automated processor.

## STORAGE REQUIREMENTS:

Store at 2-8°C. Do not use the kit reagents beyond the expiration date. This will be valid only if reagents are stored, closed and at 2-8°C.

## STORAGE OF REAGENTS ONCE OPENED:

Reagent	Stability
VIRCLIA® MONODOSE	Once opened, use it in the same day

## STABILITY AND HANDLING OF REAGENTS:

Handle reagents in aseptic conditions to avoid microbial contaminations.

Do not let the plate dry between washing and reagent addition.

Substrate component A is light sensitive. Avoid light exposure. Substrate solution should not get in contact with acid, combustible materials and strong oxidizing or reducing agents. Make sure that no metal components come in contact with the substrate without having previously tested their compatibility.

VIRCELL, S.L. does not accept responsibility for the mishandling of the reagents included in the kit.

## RECOMMENDATIONS AND PRECAUTIONS:

1. For *in vitro* diagnosis use only. For professional use only.
2. Use kit components only. Do not mix components from different kits or manufacturers. Only components of the AUXILIARY REAGENTS kit are compatible with all VIRCLIA® references and lots.
3. Clean pipette tips must be used for every assay step. Use only clean, preferably disposable material.
4. Wear protective disposable gloves, laboratory coats and eye protection when handling specimens. Wash hands thoroughly after manipulating samples. Besides, follow all safety protocols in use in your laboratory.
5. Do not use in the event of damage to the package.
6. Never pipette by mouth.
7. Serum dilution solution, reaction wells, conjugates and calibrator in this kit include substances of animal origin. Calibrator includes as well substances of human origin. Although the human serum controls of this kit have been



tested and found negative for Hepatitis B Surface Antigen (HBsAg), Hepatitis C antibodies and Human Immunodeficiency Virus antibodies, control sera and patient specimens should be handled as potentially infectious. Reaction wells are coated with inactivated antigen. Nevertheless, they should be considered potentially infectious and handled with care. No present method can offer complete assurance that infectious agents are absent. All material should be handled and disposed as potentially infectious. Observe the local regulations for clinical waste disposal.

8. Substrate solution may be irritant to eyes, respiratory system and skin. In case of contact with this solution, rinse thoroughly with water and seek medical attention. For further information a Material Safety Data Sheet is available.

9. Do not use this product in automated processors unless they have been previously validated for that purpose.

#### SPECIMEN COLLECTION AND HANDLING:

Blood should be collected aseptically using venipuncture techniques by qualified personnel. Use of sterile or aseptic techniques will preserve the integrity of the specimen. Serum/plasma samples are to be refrigerated (2-8°C) upon collection or frozen (-20°C) if the test cannot be performed within 7 days. Samples should not be repeatedly frozen and thawed. Do not use hyperlipemic, hemolysed or contaminated samples. Samples containing particles should be clarified by centrifugation. The kit is suitable for use with serum or plasma.

#### PRELIMINARY PREPARATION OF THE REAGENTS:

All reagents supplied are ready to use.

Only the VIRCLIA® WASHING SOLUTION included in the auxiliary component kit VIRCLIA® AUXILIARY REAGENTS must be prepared in advance. Fill 50 ml of VIRCLIA® WASHING SOLUTION (20x) up to 1 litre with distilled water. Should salt crystals form in the washing concentrate during storage, warm the solution to 37°C before diluting. Once diluted, store at 2-8°C.

#### ASSAY PROCEDURE:

##### • AUTOMATED

1. Bring VIRCLIA® WASHING SOLUTION (diluted according to the instructions) to room temperature before use (approximately 1 hour).
2. Follow the Operator's Manual of the Automated Processor.

##### • MANUAL

Contact the manufacturer for further information on the manual procedure.

#### INTERNAL QUALITY CONTROL:

Each batch is subjected to internal quality control (Q.C.) testing before batch release complying with specifications stricter than validation protocol for users. Final Q.C. results for each particular lot are available.

The control material is traceable to reference sera panels internally validated.

#### VALIDATION PROTOCOL FOR USERS:

Each monodose includes one calibrator (well A) and one dilution of the calibrator used as negative control (well C). It allows the validation of the assay and kit.

RLU of the calibrator and the negative control must fall in the following ranges. Otherwise, the test is invalid and must be repeated.

Control	RLU
CALIBRATOR	2-7
NEGATIVE CONTROL	<2

#### INTERPRETATION OF RESULTS:

Antibody index= (sample RLU/calibrator RLU)

Index	Interpretation
<0.9	Negative
0.9-1.1	Equivocal
>1.1	Positive

Samples with equivocal results must be retested and/or a new sample obtained for confirmation.

Samples with indexes below 0.9 are considered as not having antibodies of the specificity and class measured by this kit.

Samples with indexes above 1.1 are considered as having antibodies of the specificity and class measured by this kit.

#### LIMITATIONS:

1. This kit is intended to be used with human serum/plasma.
2. The user of this kit is advised to carefully read and understand the package insert. Strict adherence to the protocol is necessary to obtain reliable test results. In particular, correct sample and reagent pipetting, along with careful washing and timing of the incubation steps are essential for accurate results.
3. The results of samples should be used in conjunction with clinical evaluation and other diagnostic procedures. A definitive diagnosis should be made by isolation techniques.
4. This test will not indicate the site of infection. It is not intended to replace isolation.
5. Lack of significant rise in antibody level does not exclude the possibility of infection.
6. Samples collected very early in the course of an infection may not have detectable levels of IgG. In such cases, it is recommended an IgM assay be performed or a second serum sample be obtained 14 to 21 days later to be tested in parallel with the original sample to determine seroconversion.
7. Results in IgG detection in neonates must be interpreted with caution, since maternal IgG is transferred passively from the mother to the foetus before birth. IgM assays are generally more useful indicators of infection in children below 6 months of age.
8. The results of a single-specimen antibody determination should not be used to aid in the diagnosis of recent infection. Paired samples (acute and convalescent) should be collected and tested concurrently to look for seroconversion or a significant rise in antibody level.
9. HSV-1 and HSV-2 share a high genomic and antigenic similarity. Therefore cross-reactivity in immunoassays based on complete virions cannot be ruled out.
10. The performance results showed correspond to comparative studies with commercial predicative devices in a defined population sample. Small differences can be found with different populations or different predicative devices.



**PERFORMANCES:****• SENSITIVITY AND SPECIFICITY:**

129 serum/plasma samples were assayed against commercial ELISA and IFA kits. The results were as follows:

Samples No.	Sensitivity	Specificity
129	100%	94%

Indeterminate values were omitted from the final calculations.

**• INTRA-ASSAY PRECISION:**

3 sera were individually run 10 times each serum in a single automated assay in essentially unchanged conditions.

The results were as follows:

Serum	N	% C.V.
Sample +	10	5
CAL	10	5
CN	10	10

C.V. Coefficient of variation

**• INTER-ASSAY PRECISION:**

3 sera were individually run on 5 consecutive days in 2 different automatic processors.

The results were as follows:

Serum	N	% C.V.
Sample +	10	14
CAL	10	9
CN	10	12









C.V. Coefficient of variation

**• CROSS REACTIVITY AND INTERFERENCES:**

45 samples known to be positive for other microorganisms (cytomegalovirus, varicella-zoster virus, *Candida albicans*, (CAGTA), *Treponema pallidum*, *Chlamydia trachomatis*, Epstein- Barr virus VCA, Herpes simplex 1) were assayed. 15 samples known to be positive for rheumatoid factor and antinuclear antibodies were assayed.

No cross-reactivity with cytomegalovirus (5 samples tested), varicella zoster virus (9 samples tested), *Candida albicans* (CAGTA) (5 samples tested) and *Treponema pallidum* (7 samples tested) was found. Cross reactivity with *Chlamydia trachomatis* (1 out of 8 samples tested), Epstein-Barr virus VCA (1 out of 8 samples tested) and herpes simplex virus 1 (1 out of 3 samples tested) was found. Interferences with rheumatoid factor (1 out of 6 samples tested) were found. Interferences with antinuclear antibodies specimens (1 out of 9 samples tested) were found.

**SYMBOLS USED IN LABELS:**

	In vitro diagnostic medical device
	Use by (expiration date)
	Store at x-y°C
	Contains sufficient for <n> test
	Batch code
	Catalogue number
	Consult instructions for use
	<X> wells

**BIBLIOGRAPHY:**

- Liermann K, Schäfler A, Henke A, Sauerbrei A. Evaluation of commercial herpes simplex virus IgG and IgM enzyme immunoassays. J Virol Methods. 2014 Apr;199:29-34.
- Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: herpes simplex virus infections. Med Microbiol Immunol. 2007 Jun;196(2):89-94.
- Chonmaitree, T., C. D. Baldwin, and H. L. Lucia. 1989. Role of the virology laboratory in diagnosis and management of patients with central nervous system disease. Clin Microbiol Rev 2:1-14.
- Katz, D., J. K. Hilliard, R. R. Mirkovic, and R. A. Word. 1986. ELISA for detection of IgG and IgM antibodies to HSV-1 and HSV-2 in human sera. J Virol Methods 14:43-55.
- Ohana, B., M. Lipson, N. Vered, I. Srugo, M. Ahdut, and A. Morag. 2000. Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies. Clin Diagn Lab Immunol 7:904-8.
- Sharief, M. K. and E. J. Thompson. 1990. A sensitive ELISA system for the rapid detection of virus specific IgM antibodies in the cerebrospinal fluid. J Immunol Methods 130:19-24.
- Velan, B., M. Halmann. 1978. Chemiluminescence immunoassay. A new sensitive method for determination of antigens. Immunochemistry. 15: 331-333.
- Whitehead, T.P., L.J. Kricka, T.J. Carter, G.H. Thorpe. 1979. Analytical luminescence: its potential in the clinical laboratory. Clin Chem. 25:1531-46.
- Zhao, L., L. Sun, X. Chu. 2009. Chemiluminescence immunoassay. TrAC-Trend Anal Chem. 28: 404-415.

For any questions please contact:

customerservice@vircell.com

REVISED: 2017/05

